;PMID: 12215674 ;source_file_1013.mrg ;Release 0.9 of PennBioIE ;Funded by NSF ITR EIA-0205448 ;0)section:[e:0..36] = [t:0..36] ;1)sentence:[e:42..202] = [t:42..202] ;2)section:[e:206..306] = [t:206..306] ;3)section:[e:310..417] = [t:310..417] ;4)sentence:[e:421..606] = [t:421..606] ;5)sentence:[e:607..729] = [t:607..729] ;6)sentence:[e:731..845] = [t:731..845] ;7)sentence:[e:846..960] = [t:846..960] ;8)sentence:[e:961..1090] = [t:961..1090] ;9)sentence:[e:1091..1300] = [t:1091..1300] ;10)sentence:[e:1301..1432] = [t:1301..1432] ;11)sentence:[e:1434..1658] = [t:1434..1658] ;12)sentence:[e:1659..1850] = [t:1659..1850] ;13)sentence:[e:1851..2040] = [t:1851..2040] ;14)sentence:[e:2041..2341] = [t:2041..2341] ;15)sentence:[e:2342..2574] = [t:2342..2574] ;16)section:[e:2578..2623] = [t:2578..2623] ;Token/POS Errors ;ERROR_Token in entity file but not tree[2033..2034] - ;ERROR_Token in tree file but not entity[2032..2034] - ;section 0 Span:0..36 ;Toxicol Sci. 2002 Sep;69(1):191-201. (SEC (FRAG (NNP:[0..7] Toxicol) (NNP:[8..11] Sci) (.:[11..12] .) ('':[13..17] 2002) (::[18..25] Sep;69-LRB-) (CD:[25..26] 1) (-RRB-:[26..27] -RRB-) (CD:[27..31] :191) (::[31..32] -) (CD:[32..35] 201) (.:[35..36] .))) ;sentence 1 Span:42..202 ;2,3,7,8-tetrachlorodibenzo-p-dioxin toxicity in the zebrafish embryo: local ;circulation failure in the dorsal midbrain is associated with increased ;apoptosis. ;[42..77]:substance:"2,3,7,8-tetrachlorodibenzo-p-dioxin" (SENT (UCP-HLN (NP (NP (NN:[42..77] 2,3,7,8-tetrachlorodibenzo-p-dioxin) (NN:[78..86] toxicity)) (PP-LOC (IN:[87..89] in) (NP (DT:[90..93] the) (NN:[94..103] zebrafish) (NN:[104..110] embryo)))) (::[110..111] :) (S (NP-SBJ-1 (NP (JJ:[112..117] local) (NN:[119..130] circulation) (NN:[131..138] failure)) (PP-LOC (IN:[139..141] in) (NP (DT:[142..145] the) (JJ:[146..152] dorsal) (NN:[153..161] midbrain)))) (VP (VBZ:[162..164] is) (VP (VBN:[165..175] associated) (NP-1 (-NONE-:[175..175] *)) (PP-CLR (IN:[176..180] with) (NP (JJ:[181..190] increased) (NN:[192..201] apoptosis)))))) (.:[201..202] .))) ;section 2 Span:206..306 ;Dong W, Teraoka H, Yamazaki K, Tsukiyama S, Imani S, Imagawa T, Stegeman JJ, ;Peterson RE, Hiraga T. (SEC (FRAG (NNP:[206..210] Dong) (NNP:[211..212] W) (,:[212..213] ,) (NNP:[214..221] Teraoka) (NNP:[222..223] H) (,:[223..224] ,) (NNP:[225..233] Yamazaki) (NNP:[234..235] K) (,:[235..236] ,) (NNP:[237..246] Tsukiyama) (NNP:[247..249] S,) (NNP:[250..255] Imani) (NNP:[256..258] S,) (NNP:[259..266] Imagawa) (NNP:[267..268] T) (,:[268..269] ,) (NNP:[270..278] Stegeman) (NNP:[279..281] JJ) (,:[281..282] ,) (NNP:[284..292] Peterson) (NNP:[293..295] RE) (,:[295..296] ,) (NNP:[297..303] Hiraga) (NNP:[304..306] T.))) ;section 3 Span:310..417 ;Department of Toxicology, School of Veterinary Medicine, Rakuno Gakuen ;University, Ebetsu 069-8501, Japan. (SEC (FRAG (NNP:[310..320] Department) (IN:[321..323] of) (NNP:[324..334] Toxicology) (,:[334..335] ,) (NNP:[336..342] School) (IN:[343..345] of) (NNP:[346..356] Veterinary) (NNP:[357..365] Medicine) (,:[365..366] ,) (NNP:[367..373] Rakuno) (NNP:[374..380] Gakuen) (NNP:[382..392] University) (,:[392..393] ,) (NNP:[394..400] Ebetsu) (CD:[401..404] 069) (::[404..405] -) (CD:[405..409] 8501) (,:[409..410] ,) (NNP:[411..416] Japan) (.:[416..417] .))) ;sentence 4 Span:421..606 ;Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on local circulation ;and apoptosis in the midbrain were investigated in zebrafish (Danio rerio) ;embryos during early development. ;[432..467]:substance:"2,3,7,8-tetrachlorodibenzo-p-dioxin" ;[469..473]:substance:"TCDD" (SENT (S (NP-SBJ-1 (NP (NNS:[421..428] Effects)) (PP (IN:[429..431] of) (NP (NP (NN:[432..467] 2,3,7,8-tetrachlorodibenzo-p-dioxin)) (NP (-LRB-:[468..469] -LRB-) (NN:[469..473] TCDD) (-RRB-:[473..474] -RRB-)))) (PP (IN:[475..477] on) (NP (NP (JJ:[478..483] local) (NN:[484..495] circulation)) (CC:[496..499] and) (NP (NN:[501..510] apoptosis)))) (PP-LOC (IN:[511..513] in) (NP (DT:[514..517] the) (NN:[518..526] midbrain)))) (VP (VBD:[527..531] were) (VP (VBN:[532..544] investigated) (NP-1 (-NONE-:[544..544] *)) (PP-LOC (IN:[545..547] in) (NP (NML (NML (NN:[548..557] zebrafish)) (NML (-LRB-:[558..559] -LRB-) (NNP:[559..564] Danio) (NNP:[565..570] rerio) (-RRB-:[570..571] -RRB-))) (NNS:[572..579] embryos))) (PP-TMP (IN:[581..587] during) (NP (JJ:[588..593] early) (NN:[594..605] development))))) (.:[605..606] .))) ;sentence 5 Span:607..729 ;Embryos were exposed to TCDD from 24 h post fertilization (hpf) until ;observation, in water maintained at 28.5 degrees C. ;[631..635]:substance:"TCDD" ;[641..643]:quantitative-value:"24" ;[644..665]:quantitative-units:"h post fertilization" ;[667..670]:quantitative-units:"hpf" ;[694..699]:substance:"water" ;[714..718]:quantitative-value:"28.5" ;[719..728]:quantitative-units:"degrees C" (SENT (S (NP-SBJ-1 (NNS:[607..614] Embryos)) (VP (VBD:[615..619] were) (VP (VBN:[620..627] exposed) (NP-1 (-NONE-:[627..627] *)) (PP-CLR (TO:[628..630] to) (NP (NN:[631..635] TCDD))) (PP-TMP (IN:[636..640] from) (NP (CD:[641..643] 24) (NML (NML (NN:[644..645] h) (IN:[646..650] post) (NN:[652..665] fertilization)) (NML (-LRB-:[666..667] -LRB-) (NN:[667..670] hpf) (-RRB-:[670..671] -RRB-))))) (PP-TMP (IN:[672..677] until) (NP (NN:[678..689] observation))) (,:[689..690] ,) (PP-LOC (IN:[691..693] in) (NP (NP (NN:[694..699] water)) (VP (VBN:[700..710] maintained) (NP (-NONE-:[710..710] *)) (PP (IN:[711..713] at) (NP (CD:[714..718] 28.5) (NNS:[719..726] degrees) (NN:[727..728] C)))))))) (.:[728..729] .))) ;sentence 6 Span:731..845 ;TCDD decreased blood flow in the mesencephalic vein, the only vessel ;perfusing the dorsal midbrain of the embryo. ;[731..735]:substance:"TCDD" (SENT (S (NP-SBJ (NN:[731..735] TCDD)) (VP (VBD:[736..745] decreased) (NP (NN:[746..751] blood) (NN:[752..756] flow)) (PP-LOC (IN:[757..759] in) (NP (NP (DT:[760..763] the) (JJ:[764..777] mesencephalic) (NN:[778..782] vein)) (,:[782..783] ,) (NP (NP (DT:[784..787] the) (JJ:[788..792] only) (NN:[793..799] vessel)) (VP (VBG:[800..809] perfusing) (NP (NP (DT:[811..814] the) (JJ:[815..821] dorsal) (NN:[822..830] midbrain)) (PP (IN:[831..833] of) (NP (DT:[834..837] the) (NN:[838..844] embryo))))))))) (.:[844..845] .))) ;sentence 7 Span:846..960 ;At 50 hpf, blood flow was maximally reduced in this vessel and gradually ;returned to the control level at 60 hpf. ;[849..851]:quantitative-value:"50" ;[852..855]:quantitative-units:"hpf" ;[953..955]:quantitative-value:"60" ;[956..959]:quantitative-units:"hpf" (SENT (S (PP-TMP (IN:[846..848] At) (NP (CD:[849..851] 50) (NN:[852..855] hpf))) (,:[855..856] ,) (NP-SBJ-1 (NN:[857..862] blood) (NN:[863..867] flow)) (VP (VP (VBD:[868..871] was) (ADVP (RB:[872..881] maximally)) (VP (VBN:[882..889] reduced) (NP-1 (-NONE-:[889..889] *)) (PP-LOC (IN:[891..893] in) (NP (DT:[894..898] this) (NN:[899..905] vessel))))) (CC:[906..909] and) (VP (ADVP (RB:[910..919] gradually)) (VBD:[920..928] returned) (PP (TO:[929..931] to) (NP (DT:[932..935] the) (NN:[936..943] control) (NN:[944..949] level))) (PP-TMP (IN:[950..952] at) (NP (CD:[953..955] 60) (NN:[956..959] hpf))))) (.:[959..960] .))) ;sentence 8 Span:961..1090 ;In contrast, blood flows in the trunk and in other vessels of the head of ;the embryo did not significantly change until 72 hpf. ;[1083..1085]:quantitative-value:"72" ;[1086..1089]:quantitative-units:"hpf" (SENT (S (PP (IN:[961..963] In) (NP (NN:[965..973] contrast))) (,:[973..974] ,) (NP-SBJ (NP (NN:[975..980] blood) (NNS:[981..986] flows)) (PP-LOC (PP (IN:[987..989] in) (NP (DT:[990..993] the) (NN:[994..999] trunk))) (CC:[1000..1003] and) (PP (IN:[1004..1006] in) (NP (NP (JJ:[1007..1012] other) (NNS:[1013..1020] vessels)) (PP (IN:[1021..1023] of) (NP (NP (DT:[1024..1027] the) (NN:[1028..1032] head)) (PP (IN:[1033..1035] of) (NP (DT:[1036..1039] the) (NN:[1041..1047] embryo))))))))) (VP (VBD:[1048..1051] did) (RB:[1052..1055] not) (ADVP (RB:[1056..1069] significantly)) (VP (VB:[1070..1076] change) (PP-TMP (IN:[1077..1082] until) (NP (CD:[1083..1085] 72) (NN:[1086..1089] hpf))))) (.:[1089..1090] .))) ;sentence 9 Span:1091..1300 ;Furthermore, TCDD exposure caused apoptosis in the midbrain at 60 hpf, and ;the TCDD dose response relationship for this effect was similar to that for ;reduced blood flow in the mesencephalic vein at 50 hpf. ;[1104..1108]:substance:"TCDD" ;[1155..1157]:quantitative-value:"60" ;[1158..1161]:quantitative-units:"hpf" ;[1171..1175]:substance:"TCDD" ;[1293..1295]:quantitative-value:"50" ;[1296..1299]:quantitative-units:"hpf" (SENT (S (S (ADVP (RB:[1091..1102] Furthermore)) (,:[1102..1103] ,) (NP-SBJ (NN:[1104..1108] TCDD) (NN:[1109..1117] exposure)) (VP (VBD:[1119..1125] caused) (NP (NN:[1126..1135] apoptosis)) (PP-LOC (IN:[1136..1138] in) (NP (DT:[1139..1142] the) (NN:[1143..1151] midbrain))) (PP-TMP (IN:[1152..1154] at) (NP (CD:[1155..1157] 60) (NN:[1158..1161] hpf))))) (,:[1161..1162] ,) (CC:[1163..1166] and) (S (NP-SBJ (NP (DT:[1167..1170] the) (NML (NN:[1171..1175] TCDD) (NN:[1176..1180] dose) (NN:[1181..1189] response)) (NN:[1191..1203] relationship)) (PP (IN:[1204..1207] for) (NP (DT:[1208..1212] this) (NN:[1213..1219] effect)))) (VP (VBD:[1220..1223] was) (ADJP-PRD (JJ:[1224..1231] similar) (PP (TO:[1232..1234] to) (NP (NP (DT:[1235..1239] that)) (PP (IN:[1240..1243] for) (NP (JJ:[1244..1251] reduced) (NN:[1252..1257] blood) (NN:[1258..1262] flow))) (PP-LOC (IN:[1263..1265] in) (NP (DT:[1266..1269] the) (JJ:[1271..1284] mesencephalic) (NN:[1285..1289] vein))) (PP-TMP (IN:[1290..1292] at) (NP (CD:[1293..1295] 50) (NN:[1296..1299] hpf)))))))) (.:[1299..1300] .))) ;sentence 10 Span:1301..1432 ;The effects of TCDD on apoptosis in the midbrain, but not on blood flow, ;were abolished by Z-VAD-FMK, a general caspase inhibitor. ;[1316..1320]:substance:"TCDD" ;[1393..1402]:substance:"Z-VAD-FMK" ;[1414..1421]:substance:"caspase" ;[1422..1431]:substance:"inhibitor" (SENT (S (NP-SBJ-1 (NP (DT:[1301..1304] The) (NNS:[1305..1312] effects)) (PP (IN:[1313..1315] of) (NP (NN:[1316..1320] TCDD))) (PP (PP (IN:[1321..1323] on) (NP (NP (NN:[1324..1333] apoptosis)) (PP-LOC (IN:[1334..1336] in) (NP (DT:[1337..1340] the) (NN:[1341..1349] midbrain))))) (,:[1349..1350] ,) (CC:[1352..1355] but) (RB:[1356..1359] not) (PP (IN:[1360..1362] on) (NP (NN:[1363..1368] blood) (NN:[1369..1373] flow))))) (,:[1373..1374] ,) (VP (VBD:[1375..1379] were) (VP (VBN:[1380..1389] abolished) (NP-1 (-NONE-:[1389..1389] *)) (PP (IN:[1390..1392] by) (NP-LGS (NP (NN:[1393..1402] Z-VAD-FMK)) (,:[1402..1403] ,) (NP (DT:[1404..1405] a) (JJ:[1406..1413] general) (NN:[1414..1421] caspase) (NN:[1422..1431] inhibitor)))))) (.:[1431..1432] .))) ;sentence 11 Span:1434..1658 ;TCDD effects on both endpoints were mimicked by beta-naphthoflavone (BNF), an ; aryl hydrocarbon receptor (AHR) agonist, and almost abolished by concomitant ; exposure to TCDD and alpha-naphthoflavone (ANF), an AHR antagonist. ;[1434..1438]:substance:"TCDD" ;[1482..1501]:substance:"beta-naphthoflavone" ;[1503..1506]:substance:"BNF" ;[1513..1538]:substance:"aryl hydrocarbon receptor" ;[1540..1543]:substance:"AHR" ;[1545..1552]:substance:"agonist" ;[1603..1607]:substance:"TCDD" ;[1612..1632]:substance:"alpha-naphthoflavone" ;[1634..1637]:substance:"ANF" ;[1643..1646]:substance:"AHR" ;[1647..1657]:substance:"antagonist" (SENT (S (NP-SBJ-1 (NP (NN:[1434..1438] TCDD) (NNS:[1439..1446] effects)) (PP (IN:[1447..1449] on) (NP (DT:[1450..1454] both) (NNS:[1455..1464] endpoints)))) (VP (VBD:[1465..1469] were) (VP (VP (VBN:[1470..1478] mimicked) (NP-1 (-NONE-:[1478..1478] *)) (PP (IN:[1479..1481] by) (NP-LGS (NP (NP (NN:[1482..1501] beta-naphthoflavone)) (NP (-LRB-:[1502..1503] -LRB-) (NN:[1503..1506] BNF) (-RRB-:[1506..1507] -RRB-))) (,:[1507..1508] ,) (NP (DT:[1509..1511] an) (NML (NML (NN:[1513..1517] aryl) (NN:[1518..1529] hydrocarbon) (NN:[1530..1538] receptor)) (NML (-LRB-:[1539..1540] -LRB-) (NN:[1540..1543] AHR) (-RRB-:[1543..1544] -RRB-))) (NN:[1545..1552] agonist))))) (,:[1552..1553] ,) (CC:[1554..1557] and) (VP (ADVP (RB:[1558..1564] almost)) (VBN:[1565..1574] abolished) (NP-1 (-NONE-:[1574..1574] *)) (PP (IN:[1575..1577] by) (NP-LGS (NP (JJ:[1578..1589] concomitant) (NN:[1591..1599] exposure)) (PP (TO:[1600..1602] to) (NP (NP (NN:[1603..1607] TCDD)) (CC:[1608..1611] and) (NP (NP (NP (NN:[1612..1632] alpha-naphthoflavone)) (NP (-LRB-:[1633..1634] -LRB-) (NN:[1634..1637] ANF) (-RRB-:[1637..1638] -RRB-))) (,:[1638..1639] ,) (NP (DT:[1640..1642] an) (NN:[1643..1646] AHR) (NN:[1647..1657] antagonist)))))))))) (.:[1657..1658] .))) ;sentence 12 Span:1659..1850 ;Concomitant exposure to TCDD and either an inhibitor of cytochrome P450 ;(CYP) (SKF525A or miconazole) or an antioxidant (N-acetylcysteine or ;ascorbic acid) inhibited these effects of TCDD. ;[1684..1688]:substance:"TCDD" ;[1703..1712]:substance:"inhibitor" ;[1716..1731]:cyp450:"cytochrome P450" ;[1733..1736]:cyp450:"CYP" ;[1739..1746]:substance:"SKF525A" ;[1751..1761]:substance:"miconazole" ;[1769..1780]:substance:"antioxidant" ;[1782..1798]:substance:"N-acetylcysteine" ;[1802..1815]:substance:"ascorbic acid" ;[1845..1849]:substance:"TCDD" (SENT (S (NP-SBJ (NP (JJ:[1659..1670] Concomitant) (NN:[1672..1680] exposure)) (PP (TO:[1681..1683] to) (NP (NP (NN:[1684..1688] TCDD)) (CC:[1689..1692] and) (NP (RB:[1693..1699] either) (NP (NP (DT:[1700..1702] an) (NN:[1703..1712] inhibitor)) (PP (IN:[1713..1715] of) (NP (NP (NN:[1716..1726] cytochrome) (NN:[1727..1731] P450)) (NP (-LRB-:[1732..1733] -LRB-) (NN:[1733..1736] CYP) (-RRB-:[1736..1737] -RRB-)))) (PRN (-LRB-:[1738..1739] -LRB-) (NP (NN:[1739..1746] SKF525A) (CC:[1747..1749] or) (NN:[1751..1761] miconazole)) (-RRB-:[1761..1762] -RRB-))) (CC:[1763..1765] or) (NP (DT:[1766..1768] an) (NN:[1769..1780] antioxidant) (PRN (-LRB-:[1781..1782] -LRB-) (NP (NP (NN:[1782..1798] N-acetylcysteine)) (CC:[1799..1801] or) (NP (JJ:[1802..1810] ascorbic) (NN:[1811..1815] acid))) (-RRB-:[1815..1816] -RRB-))))))) (VP (VBD:[1817..1826] inhibited) (NP (NP (DT:[1828..1833] these) (NNS:[1834..1841] effects)) (PP (IN:[1842..1844] of) (NP (NN:[1845..1849] TCDD))))) (.:[1849..1850] .))) ;sentence 13 Span:1851..2040 ;The incidence of apoptosis in the midbrain was inversely related to blood ;flow in this brain region following these various treatments and graded TCDD ;exposure concentrations (r = -0.91). ;[1999..2003]:substance:"TCDD" (SENT (S (NP-SBJ-1 (NP (DT:[1851..1854] The) (NN:[1855..1864] incidence)) (PP (IN:[1865..1867] of) (NP (NN:[1868..1877] apoptosis))) (PP-LOC (IN:[1878..1880] in) (NP (DT:[1881..1884] the) (NN:[1885..1893] midbrain)))) (VP (VBD:[1894..1897] was) (ADVP (RB:[1898..1907] inversely)) (VP (VBN:[1909..1916] related) (NP-1 (-NONE-:[1916..1916] *)) (PP-CLR (TO:[1917..1919] to) (NP (NP (NN:[1920..1925] blood) (NN:[1926..1930] flow)) (PP-LOC (IN:[1931..1933] in) (NP (DT:[1934..1938] this) (NN:[1939..1944] brain) (NN:[1945..1951] region))))) (PP (VBG:[1952..1961] following) (NP (NP (DT:[1962..1967] these) (JJ:[1968..1975] various) (NNS:[1976..1986] treatments)) (CC:[1988..1991] and) (NP (VBN:[1992..1998] graded) (NML (NN:[1999..2003] TCDD) (NN:[2004..2012] exposure)) (NNS:[2013..2027] concentrations)))) (PRN (-LRB-:[2028..2029] -LRB-) (S (NP-SBJ (NN:[2029..2030] r)) (VP (SYM:[2031..2032] =) (NP (SYM:[2032..2034] -) (CD:[2034..2038] 0.91)))) (-RRB-:[2038..2039] -RRB-)))) (.:[2039..2040] .))) ;sentence 14 Span:2041..2341 ;The same range of TCDD exposure concentrations that reduced blood flow and ;increased apoptosis in the midbrain greatly enhanced CYP1A mRNA expression ;and immunoreactivity at 50 hpf in endothelial cells of blood vessels ;including the mesencephalic vein and the heart, but not the brain ;parenchyma. ;[2059..2063]:substance:"TCDD" ;[2171..2181]:substance:"CYP1A mRNA" ;[2217..2219]:quantitative-value:"50" ;[2220..2223]:quantitative-units:"hpf" (SENT (S (NP-SBJ (NP (DT:[2041..2044] The) (JJ:[2045..2049] same) (NN:[2050..2055] range)) (PP (IN:[2056..2058] of) (NP (NP (NML (NN:[2059..2063] TCDD) (NN:[2065..2073] exposure)) (NNS:[2074..2088] concentrations)) (SBAR (WHNP-4 (WDT:[2089..2093] that)) (S (NP-SBJ-4 (-NONE-:[2093..2093] *T*)) (VP (VP (VBD:[2094..2101] reduced) (NP (NN:[2102..2107] blood) (NN:[2108..2112] flow))) (CC:[2113..2116] and) (VP (VBD:[2117..2126] increased) (NP (NN:[2127..2136] apoptosis))) (PP-LOC (IN:[2137..2139] in) (NP (DT:[2140..2143] the) (NN:[2145..2153] midbrain))))))))) (ADVP (RB:[2154..2161] greatly)) (VP (VP (VBD:[2162..2170] enhanced) (NP (NP (NML-1 (NN:[2171..2176] CYP1A) (NN:[2177..2181] mRNA)) (NN:[2182..2192] expression)) (CC:[2193..2196] and) (NP (NML-1 (-NONE-:[2196..2196] *P*)) (NN:[2197..2213] immunoreactivity))) (PP-TMP (IN:[2214..2216] at) (NP (CD:[2217..2219] 50) (NN:[2220..2223] hpf))) (PP-LOC (IN:[2225..2227] in) (NP (NP (JJ:[2228..2239] endothelial) (NNS:[2240..2245] cells)) (PP (IN:[2246..2248] of) (NP (NP (NN:[2249..2254] blood) (NNS:[2255..2262] vessels)) (PP (VBG:[2263..2272] including) (NP=2 (NP (DT:[2273..2276] the) (JJ:[2277..2290] mesencephalic) (NN:[2291..2295] vein)) (CC:[2296..2299] and) (NP (DT:[2300..2303] the) (NN:[2305..2310] heart))))))))) (,:[2310..2311] ,) (CC:[2312..2315] but) (VP (RB:[2316..2319] not) (NP=2 (DT:[2320..2323] the) (NN:[2324..2329] brain) (NN:[2330..2340] parenchyma)))) (.:[2340..2341] .))) ;sentence 15 Span:2342..2574 ;Taken together, these results suggest that TCDD induces apoptosis in the ;midbrain of the zebrafish embryo secondary to local circulation failure, ;which could be related to AHR activation, induction of CYP1A, and oxidative ;stress. ;[2386..2390]:substance:"TCDD" ;[2516..2519]:substance:"AHR" ;[2546..2551]:cyp450:"CYP1A" (SENT (S (S-ADV (NP-SBJ-2 (-NONE-:[2342..2342] *)) (VP (VBN:[2342..2347] Taken) (NP-2 (-NONE-:[2347..2347] *)) (ADVP (RB:[2348..2356] together)))) (,:[2356..2357] ,) (NP-SBJ (DT:[2358..2363] these) (NNS:[2364..2371] results)) (VP (VBP:[2372..2379] suggest) (SBAR (IN:[2380..2384] that) (S (NP-SBJ (NN:[2386..2390] TCDD)) (VP (VBZ:[2391..2398] induces) (NP (NP (NP (NN:[2399..2408] apoptosis)) (PP-LOC (IN:[2409..2411] in) (NP (NP (DT:[2412..2415] the) (NN:[2416..2424] midbrain)) (PP (IN:[2425..2427] of) (NP (DT:[2428..2431] the) (NN:[2432..2441] zebrafish) (NN:[2442..2448] embryo)))))) (PP (JJ:[2449..2458] secondary) (PP (TO:[2459..2461] to) (NP (NP (JJ:[2463..2468] local) (NN:[2469..2480] circulation) (NN:[2481..2488] failure)) (,:[2488..2489] ,) (SBAR (WHNP-1 (WDT:[2490..2495] which)) (S (NP-SBJ-1 (-NONE-:[2495..2495] *T*)) (VP (MD:[2496..2501] could) (VP (VB:[2502..2504] be) (VP (VBN:[2505..2512] related) (NP-1 (-NONE-:[2512..2512] *)) (PP-CLR (TO:[2513..2515] to) (NP (NP (NN:[2516..2519] AHR) (NN:[2520..2530] activation)) (,:[2530..2531] ,) (NP (NP (NN:[2532..2541] induction)) (PP (IN:[2543..2545] of) (NP (NN:[2546..2551] CYP1A)))) (,:[2551..2552] ,) (CC:[2553..2556] and) (NP (JJ:[2557..2566] oxidative) (NN:[2567..2573] stress))))))))))))))))) (.:[2573..2574] .))) ;section 16 Span:2578..2623 ;PMID: 12215674 [PubMed - indexed for MEDLINE] (SEC (FRAG (NNP:[2578..2582] PMID) (::[2582..2583] :) (CD:[2584..2592] 12215674) (NN:[2593..2594] -LSB-) (NNP:[2594..2600] PubMed) (::[2601..2602] -) (NN:[2603..2610] indexed) (IN:[2611..2614] for) (NNP:[2615..2623] MEDLINE-RSB-)))